Difference between revisions of "Prostate cancer, BRCA-mutated"
Jump to navigation
Jump to search
(Created page with "{| class="wikitable" style="text-align:center; width:100%;" ! colspan="2" style="color:white; font-size:125%; background-color:#08519c" align="center" |'''Page editor''' ! col...") |
|||
| Line 35: | Line 35: | ||
|- | |- | ||
|} | |} | ||
| − | ''Note: this study is the | + | ''Note: this study is the basis of FDA approval; however, no dosing details are provided on CT.gov and there are no published manuscripts to date.'' |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Rucaparib (Rubraca)]] | *[[Rucaparib (Rubraca)]] | ||
Revision as of 18:43, 2 May 2021
| Page editor | Section editor | ||
|---|---|---|---|
 |
Laura S. Graham, MD University of Washington Fred Hutchinson Cancer Research Center Seattle, WA  LauraGrahamMD
|
 |
Ali Raza Khaki, MD Stanford University Palo Alto, CA arkhaki
|
7 regimens on this page
8 variants on this page
|
Note: this page has regimens which are specific to prostate cancer that is BRCA-mutated. Please see the main prostate cancer page for other regimens.
Metastatic castration-resistant
Rucaparib monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| (TRITON2) | 2017-NR | Phase II (RT) |
Note: this study is the basis of FDA approval; however, no dosing details are provided on CT.gov and there are no published manuscripts to date.
Targeted therapy
References
- TRITON2: NCT02952534